e-Therapeutics plc Total Voting Rights (0086A)
31 Enero 2022 - 12:59AM
UK Regulatory
TIDMETX
RNS Number : 0086A
e-Therapeutics plc
31 January 2022
e-therapeutics plc
("e-therapeutics" or the "Company")
Total Voting Rights
Oxford, UK, 31 January 2022 - e-therapeutics plc (AIM: ETX;
OTCQX; ETXPF), a specialist in computational drug discovery with a
focus on developing RNA interference ("RNAi") therapeutics,
announces that in accordance with the Financial Conduct Authority's
Disclosure and Transparency Rules, the Company has 514,571,069
ordinary shares of 0.1 pence each in issue, none of which are held
in treasury. Therefore, the total number of voting rights in the
Company is 514,571,069.
The above figure of 514,571,069 may be used by shareholders in
the Company as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change in their interest in, the share capital of the
Company.
Enquiries :
e-therapeutics plc Tel: +44 (0)1993 883
125
Ali Mortazavi, CEO www.etherapeutics.co.uk
Laura Roca-Alonso, CBO
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate
Broking)
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company integrating
computational power and biology to accelerate the discovery of
life-transforming medicines. The Company has developed and
validated a powerful, disease and modality agnostic computational
approach to drug discovery, leveraging its industry-leading
expertise in network biology to fully capture and interrogate human
disease complexity.
The Company's multi-disciplinary team builds computational
models of biological functions to transform the search for new
medicines, interventions, mechanisms and genetic support. Its
biology-led in silico laboratory enables rapid hypothesis
generation and phenotypic screening of millions of compounds
leading to 100-1000x higher hit rates in the wet lab and successful
mode of action elucidation. Novel targets can also be identified,
prioritised and assessed. Harnessing internal target gene
discoveries, e-therapeutics is currently building an in-house
pipeline of RNAi based medicines, using its proprietary
GalNAc-siRNA technology.
e-therapeutics has deployed and validated its disease-agnostic
computational drug discovery platform both in house and with
partners, including Novo Nordisk, Galapagos NV and a US-based, top
5 pharmaceutical company.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRZZGZMMRMGZZM
(END) Dow Jones Newswires
January 31, 2022 01:59 ET (06:59 GMT)
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De May 2023 a May 2024